Eli Lilly And Company (LLY): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.2%. By the end of trading, Eli Lilly and Company rose $0.87 (1.7%) to $52.18 on average volume. Throughout the day, 4,146,263 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,262,200 shares. The stock ranged in a price between $51.28-$52.40 after having opened the day at $51.36 as compared to the previous trading day's close of $51.31. Other companies within the Health Care sector that increased today were: Genvec ( GNVC), up 80.5%, GW Pharmaceuticals PLC ADR ( GWPH), up 61.4%, Rochester Medical Corporation ( ROCM), up 44.2% and Astex Pharmaceuticals ( ASTX), up 23.8%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.9 billion and is part of the drugs industry. Shares are up 4.0% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and increase in stock price during the past year. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, MiMedx Group ( MDXG), down 36.5%, Unilife Corporation ( UNIS), down 14.7%, Arqule ( ARQL), down 8.0% and Vivus ( VVUS), down 7.8% , were all laggards within the health care sector with Questcor Pharmaceuticals ( QCOR) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices